The JAK2 V617F mutation in patients with cerebral venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 998-1003

  Passamonti, S M ^a   Biguzzi, E ^a   Cazzola, M ^b   Franchi, F ^a   Gianniello, F ^a   Bucciarelli, P ^a   Pietra, D ^b   Mannucci, P M ^a   Martinelli, I ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cerebral sinus venous thrombosis; Myeloproliferative neoplasm; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; JANUS KINASE 2; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; JAK2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BODY MASS; BONE MARROW BIOPSY; CARDIOVASCULAR RISK; CEREBRAL SINUS THROMBOSIS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; ORAL CONTRACEPTION; POLYCYTHEMIA; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; TELECONSULTATION; THROMBOCYTHEMIA; THROMBOPHILIA; BLOOD; BLOOD CLOTTING; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; ITALY; MIDDLE AGED; MORTALITY; MUTATION; MYELOPROLIFERATIVE DISORDER; OCCLUSIVE CEREBROVASCULAR DISEASE; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; TIME; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INTRACRANIAL THROMBOSIS; ITALY; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84861705317     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04719.x     Document Type: Article

References (31)

1. Campbell PJ, Green AR. The myeloprolifertaive disorders. N Engl J Med 2006; 355: 2452-66.
2. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989; 67: 818-25.
3. Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Galone G, Pileri A. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocytemia. Ann Haematol 1999; 78: 539-43.
4. Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008; 143: 307-20.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg IR, Tichelli A, Cazzola M, Skoda RC. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
6. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
7. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myelopoliferative neoplasms. CA Cancer J Clin 2009; 59: 171-91.
8. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-14.
9. Colaizzo D, Amitrano L, Iannacone L, Vergura P, Cappucci F, Grandone E, Guardascione MA, Margaglione M. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44: 412-16.
10. Bellucci S, Cassinat B, Bonnin N, Marzac C, Crassard I. The V617F JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorders. Thromb Haemost 2008; 99: 1119-20.
11. De Stefano V, Rossi E, Za T, Chiusolo P, Leone G. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal. Thromb Haemost 2008; 99: 1121.
12. Xavier SG, Gadelha T, Schaffel R, Britto L, Pimenta G, Dias Ribeiro D, de Paula Sabino A, Pires V, Zalcberg Renault I, Spector N. Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagul Fibrinol 2008; 19: 468-9.
13. Koopman K, Mulder AB, De Heyser J, Luijckx GJ, van der Meer J. JAK2-V617F mutation in cerebral venous thrombosis. J Thromb Haemost 2009; 7: 1039-40.
14. - myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-23.
15. Xavier SG, Gadelha T, Rezende SM, Zalcberg IR, Spector N. JAK2 F617F mutation in patients with thrombosis: to screen or not to screen? Int J Lab Hematol 2011; 33: 117-24.
16. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M for the STROBE initiative. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: W163-94.
17. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
19. Tripodi A. Review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. Semin Thromb Haemost 2005; 31: 25-32.
20. Pengo V, Tripodi A, Reber G, Rand JH, Ortel L, Galli M, De Groot G. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737-40.
21. Zighetti ML, Cattaneo M, Falcon CR, Lombardi R, Harari S, Savoritto S, Mannucci PM. Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. Thromb Res 1997; 85: 279-82.
22. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-82.
23. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-9.
24. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117: 2813-16.
25. Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009; 94: 1484-8.
26. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecule. Exp Hematol 2007; 35: 702-11.
27. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, et al. Recurrent thrombosis in patients with polycytemia vera and essential thrombocytemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372-80.
28. Einhäupl K, Stam J, Bousser MG, de Bruijn SFTM, Ferro JM, Martinelli I, Masuhr F. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229-35.
29. Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121: 2740-6.
30. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. ACCP evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 454S-545S.
31. Vannucchi AM. From palliation to targeted therapy in myelofibrosis. N Engl J Med 2010; 363: 1180-2.